Search - tctmd.com

Displaying 201 - 220 of 586

Sort: Relevancy | Date

News Daily News

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Michael O'Riordan

February 28, 2016

News Daily News

‘Smoker’s Paradox’ Eliminated With Double Dose of Clopidogrel: GRAVITAS Analysis

Michael O'Riordan

February 28, 2016

News Daily News

Ticagrelor Loading Dose Provides Faster Platelet Inhibition Than Clopidogrel in Ad Hoc PCI

February 09, 2016

News Daily News

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Yael L. Maxwell

December 22, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Yael L. Maxwell

December 22, 2015

News Daily News

Según un Análisis los Beneficios Hemorrágico de la Bivalirudina Disminuyen a medida que Avanza la PCI

December 14, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Daily News

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

December 14, 2015

News Conference News AHA 2015

Varenicline Helps ACS Patients Quit Smoking, But Effect Wanes

November 12, 2015

News Daily News

药代动力学研究确认了吗啡对替卡格雷的负面影响

October 29, 2015

News Daily News

Un Estudio Farmacocinético Confirma Preocupantes Efectos de la Morfina sobre Ticagrelor

October 29, 2015

News Daily News

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

October 29, 2015

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Presentation TCT 2015

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Presenter: Steven R. Bailey, Patrick W. Serruys, Renato Valenti

October 15, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

October 14, 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Presenter: Eric Boersma, E. Magnus Ohman, Giuseppe Biondi-Zoccai

October 12, 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.